Dodge & Cox Reduces $251M in Elanco Animal Health Incorporated ($ELAN)
Dodge & Cox reduced its stake in Elanco Animal Health by over 10 million shares.
Key Points
- Dodge & Cox cut its position in Elanco Animal Health by 10,140,205 shares, reducing its stake by 12.8% to 68,944,100 shares.
- Elanco Animal Health's stock recently traded around $23.04, with a market cap of approximately $12 billion and a 52-week range of $13.16 to $27.72.
- The filing reflects Dodge & Cox's holdings as of the reporting period and may not represent its current position.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Dodge & Cox has reduced its stake in Elanco Animal Health Incorporated (ELAN), according to its latest Form 13F filing with the SEC. The investment firm cut its holdings by 10,140,205 shares, a 12.8% decrease, leaving it with 68,944,100 shares valued at about $1.59 billion. This change reflects the firm's position as of the reporting period and may not indicate its current stance.
What Changed in Dodge & Cox's Elanco Position
Dodge & Cox trimmed its investment in Elanco Animal Health by over 10 million shares, bringing its total holdings to approximately 68.9 million shares. This reduction represents a 12.8% decrease from its previous position of 79,084,305 shares, with the shares now valued at roughly $1.59 billion.
Elanco Animal Health Incorporated Stock Up 3.4%
Shares of Elanco Animal Health were trading around $23.04 recently. The company boasts a market capitalization of about $12 billion. It has experienced a 52-week low of $13.16 and a high of $27.72. The stock's beta is 1.696, indicating more volatility compared to the broader market. Elanco is not currently profitable, reflected in its negative EPS of -0.5.
$ELAN stock price
Daily closing prices, year to date. Not investment advice.
About Elanco Animal Health
Elanco Animal Health Incorporated, based in Indianapolis, Indiana, is a global player in the animal health industry. The company develops and markets products for both pets and farm animals, including parasiticides, vaccines, and therapeutics. Elanco's offerings help in protecting pets from parasites and treating various health conditions. For farm animals, the company provides products aimed at improving health and wellbeing, supporting livestock production. Founded in 1954, Elanco employs around 9,400 people under the leadership of CEO Jeffrey N. Simmons.
Bottom Line
Dodge & Cox's recent reduction in Elanco Animal Health shares is a notable move in its portfolio management. While the filing provides a snapshot of the firm's holdings during the reporting period, it may not reflect any changes made since then. Investors often track such filings for insights into institutional investment trends and strategies.
Get Elanco Animal Health Incorporated alerts
New 13F filings, insider trades, and analyst moves on $ELAN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.